|
|
Exchange: |
N/A |
Security
Type: |
Common |
Shares
Out: |
49,450,000 |
Market
Cap: |
1.41(B) |
Last
Volume: |
0 |
Avg
Vol: |
0 |
52
Week Range: |
$25.5 - $41.09 |
|
Level
I Sector: |
Health Care |
Level
II Sector: |
Drugs |
Level
III Sector: |
Drug Manufacturers - Major |
|
Member Indexes:
|
Rankings:
|
Insider 3 Months : - |
Insider 6 Months : - |
Insider 3/6 Months : - |
|
Guru Rank Number : 623 |
Guru Rank Value : 3 |
Guru Occurances : 1 |
|
|
|
|
|
|
|
Company Profile Pacira BioSciences is a holding company. Through its subsidiaries, Co. is focused on non-opioid pain management. Co. has three commercialized non-opioid treatments: EXPAREL® (bupivacaine liposome injectable suspension), a long-acting, local analgesic approved for postsurgical pain management; ZILRETTA® (triamcinolone acetonide extended-release injectable suspension), an extended-release, intra-articular, corticosteroid injection indicated for the management of OA knee pain; and ioveradeg®, a handheld device for delivering immediate, long-acting, drug-free pain control using controlled doses of cold temperature to a targeted nerve.
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
3m +/-:
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
Actions:
|
|
|
B |
Buy |
S |
Sell |
OE |
Option
Exercised |
A |
Acquired |
D |
Disposed |
AB |
Automatic
Buy |
AS |
Automatic
Sell |
IO |
Initial
Ownership |
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
|
|
Summary (Direct Transactions Only) |
3 Months |
6 Months |
12 Months |
24 Months |
Total Shares Bought |
0 |
0 |
0 |
0 |
Total Buy Value |
$0 |
$0 |
$0 |
$0 |
Total People Bought |
0 |
0 |
0 |
0 |
Total Buy Transactions |
0 |
0 |
0 |
0 |
Total Shares Sold |
0 |
119,323 |
133,308 |
212,417 |
Total Sell Value |
$0 |
$3,656,226 |
$4,183,075 |
$7,328,683 |
Total People Sold |
0 |
1 |
4 |
15 |
Total Sell Transactions |
0 |
3 |
7 |
42 |
End Date |
2024-03-10 |
2023-12-08 |
2023-06-09 |
2022-06-09 |
|
Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
3m +/- |
|
|
Form |
Brege Laura |
Director |
|
2017-06-14 |
4 |
A |
$0.00 |
$0 |
D/D |
1,357 |
3,845 |
|
- |
|
Hastings Paul J |
Director |
|
2017-06-14 |
4 |
A |
$0.00 |
$0 |
D/D |
1,357 |
4,562 |
|
- |
|
Riker Lauren Bullaro |
Vice President, Finance |
|
2017-06-14 |
4 |
A |
$0.00 |
$0 |
D/D |
3,000 |
10,063 |
|
- |
|
Scranton Richard |
Chief Scientific Officer |
|
2017-06-14 |
4 |
A |
$0.00 |
$0 |
D/D |
8,750 |
13,593 |
|
- |
|
Stack David M |
CEO and Chairman |
|
2017-06-14 |
4 |
A |
$0.00 |
$0 |
D/D |
40,500 |
100,059 |
|
- |
|
Weiland Robert J. |
Chief Commercial Officer |
|
2017-06-14 |
4 |
A |
$0.00 |
$0 |
D/D |
4,500 |
4,864 |
|
- |
|
Braunstein Scott |
SVP, Strategy & Corp. Dev. |
|
2017-06-14 |
4 |
A |
$0.00 |
$0 |
D/D |
11,000 |
20,982 |
|
- |
|
Jones James B |
SVP & Chief Medical Officer |
|
2017-06-14 |
4 |
A |
$0.00 |
$0 |
D/D |
7,500 |
17,313 |
|
- |
|
Reinhart Charles A. Iii |
Chief Financial Officer |
|
2017-06-14 |
4 |
A |
$0.00 |
$0 |
D/D |
8,750 |
8,750 |
|
- |
|
Riker Lauren Bullaro |
Vice President, Finance |
|
2017-06-07 |
4 |
S |
$44.37 |
$49,650 |
D/D |
(1,119) |
7,063 |
|
- |
|
Scibetta James S |
President |
|
2017-06-05 |
4 |
S |
$43.32 |
$85,169 |
D/D |
(1,966) |
25,118 |
|
- |
|
Stack David M |
CEO and Chairman |
|
2017-06-05 |
4 |
S |
$43.32 |
$186,757 |
D/D |
(4,311) |
59,559 |
|
- |
|
Dunker Kristen Marie |
CAO and General Counsel |
|
2017-06-05 |
4 |
S |
$43.32 |
$81,314 |
D/D |
(1,877) |
13,773 |
|
- |
|
Riker Lauren Bullaro |
Vice President, Finance |
|
2017-06-05 |
4 |
S |
$43.32 |
$26,036 |
D/D |
(601) |
8,182 |
|
- |
|
Braunstein Scott |
SVP, Strategy & Corp. Dev. |
|
2017-06-05 |
4 |
S |
$43.32 |
$33,271 |
D/D |
(768) |
9,982 |
|
- |
|
Jones James B |
SVP & Chief Medical Officer |
|
2017-06-05 |
4 |
S |
$43.32 |
$33,227 |
D/D |
(767) |
9,813 |
|
- |
|
Scibetta James S |
President |
|
2017-05-15 |
4 |
AS |
$51.20 |
$1,024,000 |
D/D |
(20,000) |
27,084 |
|
- |
|
Scibetta James S |
President |
|
2017-05-15 |
4 |
OE |
$5.49 |
$109,800 |
D/D |
20,000 |
47,084 |
|
- |
|
Dunker Kristen Marie |
CAO and General Counsel |
|
2017-05-15 |
4 |
AS |
$50.86 |
$1,070,145 |
D/D |
(21,041) |
15,650 |
|
- |
|
Dunker Kristen Marie |
CAO and General Counsel |
|
2017-05-15 |
4 |
OE |
$9.25 |
$220,856 |
D/D |
21,041 |
36,691 |
|
- |
|
Scibetta James S |
President |
|
2017-01-17 |
4 |
AS |
$38.39 |
$770,698 |
D/D |
(20,000) |
27,084 |
|
- |
|
Scibetta James S |
President |
|
2017-01-17 |
4 |
OE |
$1.61 |
$100,593 |
D/D |
20,000 |
47,084 |
|
- |
|
Stack David M |
CEO and Chairman |
|
2017-01-17 |
4 |
AS |
$38.37 |
$576,122 |
D/D |
(15,000) |
63,870 |
|
- |
|
Stack David M |
CEO and Chairman |
|
2017-01-17 |
4 |
OE |
$5.49 |
$82,350 |
D/D |
15,000 |
78,870 |
|
- |
|
Scibetta James S |
President |
|
2016-11-15 |
4 |
AS |
$36.50 |
$730,000 |
D/D |
(20,000) |
27,084 |
|
- |
|
574 Records found
|
|
Page 18 of 23 |
|
|
|
Transaction Code Key: |
Ownership Code Key |
|
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
|
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Acquired |
|
IO |
- Initital Ownership |
D |
- Disposed |
|
|
|
|
|
|